目的应用超声心动图技术评价心脏左室舒张功能衰竭(DHF),探讨其与脑钠肽(BNP)的关系,并观察贝那普利、缬沙坦干预DHF患者BNP水平的变化。方法 100例DHF患者随机分为两组,均行超声心动图检查,在常规抗心衰治疗的基础上,分别给予贝那普利(治疗组1,52例)和缬沙坦(治疗组2,48例)治疗,另有50例健康体检者为对照组,观察8周后血浆BNP水平变化,并对各组的差值进行比较。结果 DHF患者血BNP显著高于对照组(P<0.05);两治疗组8周前后比较,血浆BNP水平均有显著下降(P<0.001),但两组间差异无统计学意义(P=0.546)。结论 BNP检测与超声心动图技术评价左室舒张功能有较好的相关性,因此血浆BNP浓度有助于临床DHF诊断及危险分层,可作为DHF治疗后的疗效判断和预后评估的一个重要指标。贝那普利和缬沙坦均能显著降低DHF患者的血浆BNP水平,改善心功能。 Objective To evaluate the relationship between left ventricular diastolic dysfunction (DHF) and brain natriuretic peptide (BNP) using echocardiography and to observe the changes of BNP levels in patients receiving benazepril and valsartan. Methods One hundred cases of DHF were randomly divided into two groups. All patients underwent echocardiography. On the basis of conventional anti-heart failure treatment, patients were given benazepril (1,52 cases) and valsartan (treatment group 2 , 48 cases), and another 50 healthy people as the control group. The change of plasma BNP level after 8 weeks was observed, and the differences of each group were compared. Results The blood BNP level in patients with DHF was significantly higher than that in the control group (P <0.05). The levels of plasma BNP were significantly decreased in both groups before and after 8 weeks (P <0.001), but there was no significant difference between the two groups (P = 0.546 ). Conclusions There is a good correlation between BNP and echocardiography in assessing left ventricular diastolic function. Therefore, plasma BNP concentration is helpful for the diagnosis and risk stratification of clinical DHF, which can be used as an important index for judgment of therapeutic effect and prognosis after DHF treatment . Both benazepril and valsartan significantly reduced plasma BNP levels and improved cardiac function in DHF patients.